Avatrombopag Maleate
Brand name: Doptelet
Rank #471 of 500 drugs by total cost
$15.4M
Total Cost
1,156
Total Claims
$15.4M
Total Cost
75
Prescribers
$13K
Cost per Claim
12
Beneficiaries
1,167
30-Day Fills
$206K
Avg Cost/Provider
15
Avg Claims/Provider
About Avatrombopag Maleate
Avatrombopag Maleate (sold as Doptelet) was prescribed 1,156 times by 75 Medicare Part D providers in 2023, costing the program $15.4M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 468 | Prucalopride Succinate (Motegrity) | $15.7M | 22,068 |
| 469 | Ketorolac Tromethamine (Ketorolac Tromethamine) | $15.6M | 582,750 |
| 470 | Tetrabenazine (Tetrabenazine) | $15.6M | 6,326 |
| 471 | Avatrombopag Maleate (Doptelet) | $15.4M | 1,156 |
| 472 | Primidone (Primidone) | $15.3M | 450,535 |
| 473 | Fluocinonide (Fluocinonide) | $15.3M | 217,528 |
| 474 | Diclofenac Potassium (Diclofenac Potassium) | $15.2M | 96,736 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology